Latest News Year 2022 2021 2020 2019 2018 2017 2016 Search Senhwa Biosciences Announces Successful Awardee of Anticancer Pipeline, Pidnarulex, in NIH-Sponsored NExT Program Dec 01 2022 Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer’s Talazoparib for the Treatment of Prostate Cancer Oct 31 2022 Senhwa’s Pindnarulex in Combination Study with Pfizer’s Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC Jun 06 2022 At the 2022 AAD Annual Meeting Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma Mar 28 2022 Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations. Jan 25 2022 Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer Jan 20 2022 Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma Dec 16 2021 Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting Dec 14 2021 1 2 3 4 5 6